Please join us at Foley’s Silicon Valley Breakfast Briefing for a discussion on recent changes to the landscape of patent litigation as well as recent trends in business and legal practices for both defendants and plaintiffs, including:
- The Impact of Recent District Court Cases on Plaintiff’s Choice of Venue for Patent Lawsuits including the Eastern District of Texas
- Recent Trends and Considerations in Identifying “Patent-Friendly” Districts, Including Statistics on Delays and Outcomes
- The Growing Trend of Multi-Defendant Patent Cases and Developing Cost-Effective Joint Defense and Collaboration Strategies
- The Impact of Recent Case Law and Trends in Naming End-Users, Retailers, and Customers and How to Manage Indemnification Issues and Respond in Litigation
- Recent Trends and Considerations in Use of Reexamination Filings During or in Anticipation of Litigation
Guest Speaker: Harvey Anderson, General Counsel, Mozilla
The discussion will be led by Foley attorneys:
- Robert (Bob) E. Camors, Of Counsel, IP Litigation Practice
- George C. Best, Partner, IP Litigation and Appellate Practices
Foley will apply for CLE credit after the breakfast briefing.
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.